Lexipafant | Vernalis | Zacutex | platelet-activating factor (PAF)

MedKoo Cat#: 529718 | Name: Lexipafant

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lexipafant, also known as Vernalis and Zacutex, is a platelet-activating factor (PAF) receptor antagonist potentially for the treatment of acute pancreatitis, dementia, motor function disorders in HIV patients, and as well as for the prevention of certain serious renal and neurological complications experienced by patients undergoing cardiac surgery, including stroke.

Chemical Structure

Lexipafant

CAS#139133-26-9

Theoretical Analysis

MedKoo Cat#: 529718

Name: Lexipafant

CAS#: 139133-26-9

Chemical Formula: C24H32N4O4S

Exact Mass: 472.2144

Molecular Weight: 472.60

Elemental Analysis: C, 60.99; H, 6.83; N, 11.86; O, 13.54; S, 6.78

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

BB-882; DO-6; GR-167089; ISV-611; BB882; DO6; GR167089; ISV611; BB 882; DO 6; GR 167089; ISV 611; Vernalis; Zacutex

IUPAC/Chemical Name

ethyl N-methyl-N-((4-(2-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)ethyl)phenyl)sulfonyl)-L-leucinate

InChi Key

GREGWZRQHIQBFH-QHCPKHFHSA-N

InChi Code

InChI=1S/C24H32N4O4S/c1-6-32-24(29)23(15-17(2)3)27(5)33(30,31)20-9-7-19(8-10-20)12-14-28-18(4)26-21-16-25-13-11-22(21)28/h7-11,13,16-17,23H,6,12,14-15H2,1-5H3/t23-/m0/s1

SMILES Code

CC(C)C[C@@H](C(OCC)=O)N(C)S(=O)(C1=CC=C(CCN2C(C)=NC3=C2C=CN=C3)C=C1)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Lexipafant is a platelet-activating factor (PAF) antagonist that inhibits the inflammatory response and is used in the treatment of acute pancreatitis.

In vitro activity:

Lexipafant inhibited PAF-enhanced PMN .O2- (polymorphonuclear leukocyte superoxide) generation, CD11b expression and elastase release in a dose dependent fashion. Lexipafant attenuated the PAF-mediated upregulation of PMN .O2- production, CD11b expression, and elastase release in a dose dependent fashion. These data support the hypothesis that Lexipafant may reduce the severity of the inflammatory response to injury produced by PAF-enhanced activation of PMNs. Reference: J Surg Res. 1997 May;69(2):240-8. https://pubmed.ncbi.nlm.nih.gov/9224389/

In vivo activity:

The mean serum bilirubin and liver enzymes level significantly decreased, and Superoxide dismutase, catalase and glutathione peroxidase values were significantly increased in BDL (bile duct ligation)/BB-882 group when compared to BDL/Untreated group. The histopathological score was significantly less in the BDL/BB-882 group compared to the BDL/Untreated rats. In the BDL/BB-882 group was observed less fibrosis and neutrophil infiltration. These results suggest that BB-882 (lexipafant) may reduce the severity of the inflammatory response to liver injury produced by bile duct ligation in rats. Reference: Acta Gastroenterol Belg. 2006 Apr-Jun;69(2):197-202. https://pubmed.ncbi.nlm.nih.gov/16929615/

Preparing Stock Solutions

The following data is based on the product molecular weight 472.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Schwartz JD, Shamamian P, Grossi EA, Schwartz DS, Marcus SG, Steiner F, Jacobs CE, Tayyarah M, Eng K, Colvin SB, Galloway AC. Lexipafant inhibits platelet activating factor enhanced neutrophil functions. J Surg Res. 1997 May;69(2):240-8. doi: 10.1006/jsre.1997.5008. PMID: 9224389. 2. Oztürk H, Oztürk H, Dokucu AI, Otcu S. Effects of lexipafant (BB-882), a platelet activating factor receptor antagonist, on liver damage due to bile duct ligation in rats. Acta Gastroenterol Belg. 2006 Apr-Jun;69(2):197-202. PMID: 16929615. 3. Galloway SW, Kingsnorth AN. Lung injury in the microembolic model of acute pancreatitis and amelioration by lexipafant (BB-882), a platelet-activating factor antagonist. Pancreas. 1996 Aug;13(2):140-6. doi: 10.1097/00006676-199608000-00004. PMID: 8829181.

In vitro protocol:

In vivo protocol:

1. Oztürk H, Oztürk H, Dokucu AI, Otcu S. Effects of lexipafant (BB-882), a platelet activating factor receptor antagonist, on liver damage due to bile duct ligation in rats. Acta Gastroenterol Belg. 2006 Apr-Jun;69(2):197-202. PMID: 16929615. 2. Galloway SW, Kingsnorth AN. Lung injury in the microembolic model of acute pancreatitis and amelioration by lexipafant (BB-882), a platelet-activating factor antagonist. Pancreas. 1996 Aug;13(2):140-6. doi: 10.1097/00006676-199608000-00004. PMID: 8829181.

1: Oztürk H, Oztürk H, Dokucu AI, Otcu S. Effects of lexipafant (BB-882), a platelet activating factor receptor antagonist, on liver damage due to bile duct ligation in rats. Acta Gastroenterol Belg. 2006 Apr-Jun;69(2):197-202. PubMed PMID: 16929615. 2: Aldemir M, Boşnak M, Al B, Büyükbayram H, Taçyildiz I. Effects of molsidomine and lexipafant in hepatic ischaemia--reperfusion injury. Injury. 2004 Mar;35(3):232-7. PubMed PMID: 15124788. 3: Johnson CD, Kingsnorth AN, Imrie CW, McMahon MJ, Neoptolemos JP, McKay C, Toh SK, Skaife P, Leeder PC, Wilson P, Larvin M, Curtis LD. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut. 2001 Jan;48(1):62-9. PubMed PMID: 11115824; PubMed Central PMCID: PMC1728186. 4: Börjesson A, Wang X, Sun Z, Inghammar M, Truedsson L, Andersson R. Early treatment with lexipafant, a platelet-activating factor-receptor antagonist, is not sufficient to prevent pulmonary endothelial damage after intestinal ischaemia and reperfusion in rats. Dig Liver Dis. 2002 Mar;34(3):190-6. PubMed PMID: 11990391. 5: Ozgün H, Cevikel MH, Kozaci LD, Sakarya S. Lexipafant inhibits postsurgical adhesion formation. J Surg Res. 2002 Apr;103(2):141-5. PubMed PMID: 11922727. 6: Leveau P, Wang X, Sun Z, Börjesson A, Andersson E, Andersson R. Severity of pancreatitis-associated gut barrier dysfunction is reduced following treatment with the PAF inhibitor lexipafant. Biochem Pharmacol. 2005 May 1;69(9):1325-31. PubMed PMID: 15826603. 7: Schifitto G, Sacktor N, Marder K, McDermott MP, McArthur JC, Kieburtz K, Small S, Epstein LG. Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurological AIDS Research Consortium. Neurology. 1999 Jul 22;53(2):391-6. PubMed PMID: 10430432. 8: Abu-Zidan FM, Windsor JA. Lexipafant and acute pancreatitis: a critical appraisal of the clinical trials. Eur J Surg. 2002;168(4):215-9. Review. PubMed PMID: 12440758. 9: Sun Z, Wang X, Deng X, Lasson A, Soltesz V, Börjesson A, Andersson R. Beneficial effects of lexipafant, a PAF antagonist on gut barrier dysfunction caused by intestinal ischemia and reperfusion in rats. Dig Surg. 2000;17(1):57-65. PubMed PMID: 10720833. 10: Rivera JA, Werner J, Warshaw AL, Lewandrowski KB, Rattner DW, Fernández del Castillo C. Lexipafant fails to improve survival in severe necrotizing pancreatitis in rats. Int J Pancreatol. 1998 Apr;23(2):101-6. PubMed PMID: 9629507. 11: Suputtamongkol Y, Intaranongpai S, Smith MD, Angus B, Chaowagul W, Permpikul C, Simpson JA, Leelarasamee A, Curtis L, White NJ. A double-blind placebo-controlled study of an infusion of lexipafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis. Antimicrob Agents Chemother. 2000 Mar;44(3):693-6. PubMed PMID: 10681340; PubMed Central PMCID: PMC89748. 12: Schwartz JD, Shamamian P, Grossi EA, Schwartz DS, Marcus SG, Steiner F, Jacobs CE, Tayyarah M, Eng K, Colvin SB, Galloway AC. Lexipafant inhibits platelet activating factor enhanced neutrophil functions. J Surg Res. 1997 May;69(2):240-8. PubMed PMID: 9224389. 13: Wang X, Sun Z, Börjesson A, Haraldsen P, Aldman M, Deng X, Leveau P, Andersson R. Treatment with lexipafant ameliorates the severity of pancreatic microvascular endothelial barrier dysfunction in rats with acute hemorrhagic pancreatitis. Int J Pancreatol. 1999 Feb;25(1):45-52. PubMed PMID: 10211421. 14: Ulrich CD 2nd. Lexipafant in severe acute pancreatitis: the final word? Curr Gastroenterol Rep. 2001 Apr;3(2):85-7. Review. PubMed PMID: 11276374. 15: Kingsnorth AN, Galloway SW, Formela LJ. Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg. 1995 Oct;82(10):1414-20. PubMed PMID: 7489182. 16: Liu Q, Djuricin G, Rossi H, Bewsey K, Nathan C, Gattuso P, Weinstein RA, Prinz RA. The effect of lexipafant on bacterial translocation in acute necrotizing pancreatitis in rats. Am Surg. 1999 Jul;65(7):611-6; discussion 617. PubMed PMID: 10399968. 17: McKay CJ, Curran F, Sharples C, Baxter JN, Imrie CW. Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis. Br J Surg. 1997 Sep;84(9):1239-43. PubMed PMID: 9313702. 18: Imrie CW, McKay CJ. The scientific basis of medical therapy of acute pancreatitis. Could it work, and is there a role for lexipafant? Gastroenterol Clin North Am. 1999 Sep;28(3):591-9, ix. Review. PubMed PMID: 10503138. 19: Abu-Zidan FM. Hope or hype for lexipafant? Nature. 1998 Oct 1;395(6701):431. PubMed PMID: 9774090. 20: Wyncoll DL, Beale RJ. Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis. Br J Surg. 1998 Feb;85(2):279-80. PubMed PMID: 9501837.